Vis enkel innførsel

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

dc.contributor.authorSonja Zweegman, Zweegman
dc.contributor.authorClaudia A M Stege, A
dc.contributor.authorHaukås, Einar
dc.contributor.authorSchjesvold, Fredrik H
dc.contributor.authorMark-David Levin, Levin
dc.contributor.authorWaage, Anders
dc.contributor.authorRineke B L Leys, B
dc.contributor.authorSaskia K Klein, K
dc.contributor.authorSzatkowski, Damian Lukasz
dc.contributor.authorPer Axelsson, Axelsson
dc.contributor.authorTrung Hieu Do, Hieu
dc.contributor.authorDorota Knut-Bojanowska, Knut-Bojanowska
dc.contributor.authorEllen van der Spek, van
dc.contributor.authorAsta Svirskaite, Svirskaite
dc.contributor.authorAnja Klostergaard, Klostergaard
dc.contributor.authorMorten Salomo, Salomo
dc.contributor.authorCeline Blimark, Blimark
dc.contributor.authorPaula F Ypma, F
dc.contributor.authorUlf-Henrik Mellqvist, Mellqvist
dc.contributor.authorPino J Poddighe, J
dc.contributor.authorMarian Stevens-Kroef, Stevens-Kroef
dc.contributor.authorNiels W C J van de Donk, W
dc.contributor.authorPieter Sonneveld, Sonneveld
dc.contributor.authorMarkus Hansson, Hansson
dc.contributor.authorBronno van der Holt, van
dc.contributor.authorNiels Abildgaard, Abildgaard
dc.date.accessioned2021-03-12T13:48:39Z
dc.date.available2021-03-12T13:48:39Z
dc.date.created2020-12-11T17:18:49Z
dc.date.issued2020
dc.identifier.citationHaematologica. 2020, 105 (12), 2879-2882.en_US
dc.identifier.issn0390-6078
dc.identifier.urihttps://hdl.handle.net/11250/2733197
dc.language.isoengen_US
dc.publisherFerrata Storti Foundationen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleIxazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trialen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber2879-2882en_US
dc.source.volume105en_US
dc.source.journalHaematologicaen_US
dc.source.issue12en_US
dc.identifier.doi10.3324/haematol.2019.240374
dc.identifier.cristin1858897
dc.description.localcodeOpen Access, published under a Creative Commons license CC BY-NC-NDen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail
Filnavn:
Ixazomib-Thalidomide-low+dose+ ...
Størrelse:
436.0Kb
Format:
PDF
Beskrivelse:
Zweegman
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal